Follow

Submissions from 2019

Link

Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C., C. Q. Pan, B. C. Tiongson, K.Q. Hu, S-H. B. Han, M. Tong, D. Chu, J. Park, T. P. Lee, K. R. Bhamidimarri, D. Wang, and +3 additional authors

Link

Drug-Induced Liver Injury Due to Dulaglutide Use, A. V. Patel, P. M. Jotwani, and T. P. Lee

Link

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis, F. Poordad, S. Sedghi, P. J. Pockros, N. Ravendhran, R. Reindollar, M. R. Lucey, M. Epstein, L. Bank, D. Bernstein, D. R. Nelson, and +5 additional authors

Link

Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges, N. S. Samji, R. Verma, K. C. Keri, A. K. Singal, A. Ahmed, M. Rinella, D. Bernstein, M. F. Abdelmalek, and S. K. Satapathy

Submissions from 2018

Link

Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic Preface, D. E. Bernstein

PDF

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin, J. J. Feld, D. E. Bernstein, Z. Younes, H. Van Vlierberghe, L. Larsen, F. Tatsch, and P. Ferenci

Link

Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, C. K. Hung and H. C. Bodenheimer

Link

Response to Perrella et al, P. Y. Kwo, M. L. Shiffman, and D. E. Bernstein

Link

The cochrane review conclusion for Hepatitis C DAA therapies is wrong, P. Y. Kwo, M. L. Shiff, and D. E. Bernstein

Link

Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics, H. W. Lim and D. E. Bernstein

PDF

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure, F. Poordad, S. Pol, A. Asatryan, M. Buti, D. Shaw, C. Hezode, F. Felizarta, R. W. Reindollar, D. E. Bernstein, F. J. Mensa, and +10 additional authors

Link

A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy., D. K. Rex, R. Bhandari, T. Desta, M. P. DeMicco, C. Schaeffer, K. Etzkorn, C. F. Barish, R. Pruitt, B. D. Cash, D. Bernstein, and +3 additional authors

PDF

Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial, J. Thompson, N. Jones, A. Al-Khafaji, S. Malik, D. Reich, S. Munoz, R. MacNicholas, T. Hassanein, A. Duddempudi, R. Subramanian, and +33 additional authors

Link

Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography, E. Tsai and T. P. Lee

Submissions from 2017

Link

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study., D. Jones, P. F. Boudes, M. G. Swain, C. L. Bowlus, M. R. Galambos, B. R. Bacon, Y. Doerffel, N. Gitlin, D. E. Bernstein, G. M. Hirschfield, and +26 additional authors

PDF

Glecaprevir and Pibrentasvir for 12 Weeks for Hepatitis C Virus Genotype 1 Infection and Prior Direct-Acting Antiviral Treatment, F. Poordad, F. Felizarta, A. Asatryan, M. S. Sulkowski, R. W. Reindollar, C. S. Landis, S. C. Gordon, S. L. Flamm, D. E. Bernstein, F. J. Mensa, and +6 additional authors

Link

Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update, G. Shiha, A. Ibrahim, A. Helmy, S. K. Sarin, M. Omata, A. Kumar, D. Bernstien, H. Maruyama, V. Saraswat, Y. Chawla, S. Hamid, Z. Abbas, P. Bedossa, P. Sakhuja, M. Elmahatab, S. G. Lim, L. Lesmana, J. Sollano, J.D. Jia, and M. Kumar

Submissions from 2016

Link

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks, J. J. Feld, C. Moreno, R. Trinh, E. Tam, S. Bourgeois, Y. Horsmans, M. Elkhashab, D. E. Bernstein, N. S. Shulman, F. Poordad, and +7 additional authors

PDF

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial, E. J. Gane, K. V. Kowdley, D. Pound, C. A.M. Stedman, M. Davis, K. Etzkorn, S. C. Gordon, D. Bernstein, P. Y. Kwo, M. H. Nguyen, and +14 additional authors

PDF

Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study, P. Kwo, N. Gitlin, R. Nahass, D. Bernstein, K. Etzkorn, S. Rojter, E. Schiff, M. Davis, P. Ruane, J. Witek, and +8 additional authors

PDF

Efficacy of Direct-Acting Antiviral Combination for Patients with Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease, P. J. Pockros, K. R. Reddy, P. S. Mantry, E. Cohen, M. Bennett, M. S. Sulkowski, D. E. Bernstein, D. E. Cohen, N. S. Shulman, E. Lawitz, and +4 additional authors

Submissions from 2015

Link

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid, G. M. Hirschfield, A. Mason, V. Luketic, K. Lindor, S. C. Gordon, M. Mayo, K. V. Kowdley, C. Vincent, H. C. Bodhenheimer Jr., D. Shapiro, and +8 additional authors

PDF

Hepatic manifestations of non-steroidal inflammatory bowel disease therapy, R. Hirten, K. Sultan, A. Thomas, and D. E. Bernstein

Link

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders, D. Jensen, K. E. Sherman, C. Hezode, S. Pol, S. Zeuzem, V. de Ledinghen, A. Tran, M. Elkhashab, D. Bernstein, S. Noviello, and +13 additional authors

PDF

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study, D. R. Nelson, J. N. Cooper, J. P. Lalezari, E. Lawitz, P. J. Pockros, N. Gitlin, B. F. Freilich, Z. H. Younes, D. Berastein, E. A. Hughes, and +15 additional authors

Submissions from 2014

Link

Hepatitis B and C, A. T. Duddempudi and D. E. Bernstein

Link

ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV, P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Y. Luo, C. Cooper, E. Tam, R. T. Marinho, N. Tsai, K. R. Reddy, and +19 additional authors

Link

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis, K. V. Kowdley, S. C. Gordon, K. R. Reddy, L. Rossaro, D. E. Bernstein, E. Lawitz, M. L. Shiffman, E. Schiff, R. Ghalib, M. W. Fried, and +15 additional authors